Introduction: There is continued unmet medical need for new medicines across countries
especially for cancer, immunological diseases, and orphan diseases. However, there are …

We are in the midst of a technological revolution that is providing new insights into human
biology and cancer. In this era of big data, we are amassing large amounts of information …

PURPOSE To better understand the European Society for Medical Oncology-Magnitude of
Clinical Benefit Scale version 1.1 (ESMO-MCBS v1. 1) and the ASCO Value Framework Net …

Tremendous progress in treatment and outcomes has been achieved across the whole
range of haematological malignancies in the past two decades. Although cure rates for …

The rapid development of immuno-oncology (IO) therapies for multiple types of cancer has
transformed the cancer treatment landscape and brightened the long-term outlook for many …

The sixth section of our Special Task Force (STF) report reviews and comments on recent
US-oriented value assessment frameworks, specifically those published by the American …

Medicines receiving a conditional marketing authorization through Medicines Adaptive
Pathways to Patients (MAPPs) will be a challenge for payers. The “introduction” of MAPPs is …

Purpose This paper presents a comparative analysis of value-based frameworks (VBFs)
developed in the United States and Europe for both drugs and medical devices. Methods …

Background Healthcare decision makers need to make trade-offs between different
elements of value of new treatments. Multicriteria decision analysis (MCDA) provides a …

Background Decision makers are facing growing challenges in prioritizing drugs for
reimbursement because of soaring drug costs and increasing pressures on financial …